His picks have hit or miss. One bit I missed was LFIN at 5.60 and it went to 144 a few days later
What the email entails
Innovus Pharmaceuticals (INNV) with a Price Target of $0.65
& Breaking News Of Official Launch of its Amazon®, Walmart®, eBay®,
Wish® on-line stores in the United States!
???????
Dear PSP Member,
James Connelly here...
My New Monster Pick for Tuesday is: INNV
Wall Street is just Starting to Show Major Interest in INNV!
One of Wall Street's Top Analysts initiated coverage on Innovus
Pharmaceuticals, Inc. (INNV) with a price target of $.65.
According to SeeThru Equity, INNV has 300% upside from its current price!
Barchart Technical Opinion rating, just issued their Strongest Overall Average of a 100% Buy!
Additionally, what draws me to alert INNV right now is the Breaking News that just came out Jan 18th, 2018 regarding the official launch of its Amazon®, Walmart®, eBay® and Wish® on-line stores in the United States with a combined 116 Company product SKUs. Timing for YOU with this trade idea in my opinion is picture perfect. Read News Below
1. See Full News Release Here
2. See Analyst Report Issuing $.65 Price Target Here
3. See Barchart Just Issued Strong 100% Buy Here
Symbol: INNV
Co: Innovus Pharmaceuticals Inc.
Breakout Catalyst: (+)
INNV Is On Immediate ALERT!
About Innovus Pharmaceuticals Inc.
Innovus Pharmaceuticals, Inc. is a fast-growing commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality.
INNV has been making tremendous progress!
INNV has been accomplishing one major milestone after another, with accomplishments like their recent huge news that, Innovus Pharma announces Official Launch of its Amazon®, Walmart®, eBay® and Wish® On-Line Stores with a Combined 116 Product SKUs. Read news below
Pay close attention because this is the EXACT "Catalyst"
that could potentially ignite this stock to new levels!
Innovus Pharma Announces Official Launch of its Amazon®, Walmart®, eBay® and Wish® On-Line Stores with a Combined 116 Product SKUs
This Could be Game-Changing Event for Innovus Pharmaceuticals!
INNV just announced major breaking news of another very significant millstone achievement. They just announced the official launch of its Amazon®, Walmart®, eBay® and Wish® on-line stores in the United States with a combined 116 Company product SKUs. As part of this on-line product distribution, the Company also secured worldwide non-exclusive rights to sell two primary products from Antiaging Systems, Ltd.: Can-C™ and Melatonin (MZS™).
“We are very excited to announce the official launch of our Amazon®, Walmart®, eBay® and Wish® on-line stores with our current combined 116 product SKUs,” said Innovus CEO Dr. Bassam Damaj. “We are already seeing a significant increase in our month over month sales from the on-line stores and we currently expect the on-line sales to be a growing percentage of our revenues in the very near future.
“In addition, we are working on the development and launch of additional Amazon® sites in Canada, Mexico and the United Kingdom and we look forward to growing our on-line presence of our products and additional products such as Can-C™ and Melatonin (MZS™) that already have large on-line sales presences with Can-C™ alone generating on average across all sellers on Amazon® around $1.2M per year in 2017. These additional sales channels should only serve to increase the overall sales revenues we may see in the future through our ever-growing online channels,” he continued.
Investment Highlights were as follows:
Innovus Pharma just announced on January 18th, 2018 the official launch of its Amazon®, Walmart®, eBay® and Wish® on-line stores in the United States with a combined 116 Company product SKUs. As part of this on-line product distribution, the Company also secured worldwide non-exclusive rights to sell two primary products from Antiaging Systems, Ltd.: Can-C™ and Melatonin (MZS™).
FlutiCare™ launches. Innovus Pharma announced the official launch of FlutiCare™ OTC in the US on November 14, 2017. FlutiCare™ was the leading prescribed nasal steroid and form, and its OTC formulation is expected to be a significant driver of growth for Innovus in 4Q17 and 2018.
Innovus Pharma Reported nine-month net revenue of $6.4M and net loss decrease of 51.6% compared to the Same Period in 2016. Quarterly and Year-to-Date net revenue increase 18.0% and 105.8% when compared to 2016.
Innovus Pharma is likely to come in towards the bottom of its guidance for $10- $15M in revenues in 2017, due in part to the impact of weather disruptions in key markets.
Multiple Significant Milestones
Just Announced Official launch of its Amazon®, Walmart®, eBay® and Wish® on-line stores in the United States with a combined 116 Company product SKUs.
Q4 launched of FlutiCare™ in the U.S.
Five new product launches expected in 2017 (FlutiCare™ OTC, Xyralid®, Androvit® and Urocis® XR and Musclin™)
Expecting profitability entering 2018
Unique Business Strategy and Niche Market
Robust Beyond Human® Direct to Consumer Sales & Marketing Platform (reaching 20 -30 million consumers/month) and a robust online platform
Combining branded approved drugs with known, clinically tested and loyal supplements for the same indication
Experienced and Proven Management Team
FlutiCare™ should be another game-changing event for Innovus
Innovus officially launched FlutiCare™, a generic reformulation of Flonase® fluticasone propionate nasal spray for allergy symptoms, on November 14, 2017. The company has been building to the launch for the last year, and has previously commented that FlutiCare™ could reach annualized revenues of greater than $10M+ by the end of its first year on the market. Although Innovus launched FlutiCare™ mid-quarter, we do expect Fluticare™ to be meaningful to sales due to pre-orders, as well as shipments in the channel through distributors Amerisource Bergen and McKesson. FlutiCare™ is expected to be available in 10,000 independent pharmacies, as well as online through Innovus's Beyond Human platform, Amazon.com and Walmart.com.
Core products drive growth in 3Q17
Innovus reported 18% annual top line growth for its fiscal third quarter. Revenues rose to a record $2.2M in 3Q17 versus $1.9M in 3Q16, and were up 9% sequentially from $2.0M in 2Q17. Revenues for the first nine months of 2017 were $6.4M, well ahead of $3.1M in the year-ago period. Revenue was driven by steady performance from the company's top five product families: Vesele®, UriVarx™,Sensum+®, Prostogorx® and Apeaz™, each of which are tracking at an annualized revenue run rate of greater than $1M, according to management. On November 14, 2017, Innovus Pharmaceuticals Reported nine-month net revenue of $6.4M and net loss decrease of 51.6% compared to the Same Period in 2016. Quarterly and Year-to-Date net revenue increase 18.0% and 105.8% when compared to 2016. These 3Q17 results demonstrated both sequential and YoY revenue growth, reflecting a growing portfolio of OTC products. Importantly, the company officially launched its newest and highest profile product line, FlutiCare™, a nasal steroid which management expects to have a transformational impact on the company.
Price target of $.65 for Innovus
Innovous Price target is $.65 for them to $.65, which if achieved, represents substantial upside potential from its current price. The main driver of our thesis is our expectations for dramatic growth as a result of the expanding portfolio of products sold by Innovus, which should only accelerate with the launch of a potentially game-changing new product line in Fluticare™.
Barchart just Issued Strong 100% BUY
Barchart Technical Opinion rating, just issued their Strongest Overall Average of 100% Buy!
INNV looks to be in a great position right now and numerous recent developments could lead to strong upside and with their recent $.65 Price target, for them to $.65, which if achieved, represents substantial upside potential from its current price.
Put INNV on the top of you watchlist and begin your research! Once again, Barchart just issued their Strongest Overall Average of 100% Buy!
I am urging all of our members to add INNV to the top of their watch list right now, and be ready Tuesday morning at the opening bell.
Yours for greater profits,
James Connelly
Editor, PennyStockProphet
Disclaimer:
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never inv.est in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. PLEASE NOTE WELL: Neither PSP, its corporate officers, nor any of its affiliates are registered inve- st -ment advisors or broker dealers, and do not recommend to buy, hold, or sell any sec.urities Release of Liability: Through use of this website viewing or using you agree to hold PSP, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. PSP and its employees are not a Registered Inve-st-ment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. PSP encourages readers and inve-sto-rs to supplement the information in these reports with independent research and other professional adv.ice. All information on featured companies is provided by the companies profiled, or is available from public sources and PSP makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to inve-st in any such company or other financial decisions should not be made based upon the information provide herein. It should also be known that the name James Connelly is a pseudonym used by the sites author to protect his privacy. Instead PSP strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10Q, 10K, Form 8K, insider reports, Forms 3, 4, 5 Schedule 13D. PSP is compliant with the Can Spam Act of 2003. PSP does not offer such advice or analysis, and PSP further urges you to consult your own independent tax, business, financial and investment advisors. Inve.sting in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Sec.urities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, PSP has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such liability cannot be guaranteed. Inve.stors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, PSP and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. PSP is not responsible for any claims made by the companies advertised herein, nor is PSP responsible for any other promotional firm, its program or its structure. This message is meant for informational and educational purposes only and does not provide investment advice. Never make investment decisions based on anything we say. To date we have been compensated Fifty Thousand dollars USD to profile INNV. Please be advised we have been additionally compensated for investor relations and media services for INNV in the amount of Twenty-Five Thousand dollars USD by, a non-affiliated third party for marketing exposure. We do not own any shares of INNV.
CAUTION: IT IS POSSIBLE THAT ALL MONIES MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.
Unsubscribe
This message was sent to michael.haubrich23@gmail.com from James@PennyStockProphet.com
James Connelly
14 Wall Street
New York, New York 10005
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
iContact - Try it for FREE
